Evosep received a strategic investment of 37.4 million euros

Evosep, a proteomics solutions provider, has developed new solutions to make clinical proteomics 100 times more robust and 10 times faster, aiming to achieve this by fundamentally innovating the way protein-based clinical diagnostics are performed To improve the quality of life and care of patients. Recently, Evosep received a strategic investment of 37.4 million euros from Novo Holdings.

This article is transferred from: https://www.itjuzi.com/investevent/13770375
This site is only for collection, and the copyright belongs to the original author.